Observational study on ravulizumab for generalized myasthenia gravis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Polish multicenter observational study aims to collect data on the management and clinical outcomes of patients with generalized myasthenia gravis (gMG) who are receiving ravulizumab treatment. The study will follow patients for up to 42 months, including a 6-month baseline period and 36 months of follow-up, to gather longitudinal data on their health outcomes. It focuses on patients who are naive to complement inhibitors and are treated under the National Drug Program in Poland.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
* Patients willing to participate in the study and signed Informed Consent Form (ICF).
* Vaccination against N. meningitidis

Exclusion Criteria:

* Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP.
* Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Where it's running

• Research Site
  Bydgoszcz, Poland Recruiting
• Research Site
  Gdansk, Poland Recruiting
• Research Site
  Katowice, Poland Recruiting
• Research Site
  Krakow, Poland Recruiting
• Research Site
  L Dz, Poland Recruiting
• Research Site
  Lublin, Poland Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MG patient registry to track long-term experiences and treatment patterns

  This registry collects information from adults with myasthenia gravis to see how symptoms and quality of life change over time and how treatments relate to those changes.

  Recruiting Autoimmune Neurology Alliance · Framingham, Massachusetts · NCT07761026

• Panorama: Neuromuscular Organoids to understand refractory AChR+ myasthenia gravis

  This study tests neuromuscular organoids built from stem cells to see if they reveal why some people with AChR-positive myasthenia gravis don’t respond to standard treatments.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07717281

• Claseprubart in adults with generalized myasthenia gravis

  This study tests whether claseprubart can help adults with generalized myasthenia gravis when compared with placebo.

  Recruiting at 11 sites Phase 3 Dianthus Therapeutics · Pasadena, California and 11 other locations · NCT07647510

• Aritinercept for generalized myasthenia gravis

  This study tests whether aritinercept is safe and helpful for adults with generalized myasthenia gravis compared with placebo.

  Recruiting at 11 sites Phase 1/2 Aurinia Pharmaceuticals Inc. · Pasadena, California and 10 other locations · NCT07596901

• Ravulizumab for Generalized Myasthenia Gravis in Chinese Adults

  This trial tests ravulizumab in Chinese adults with generalized myasthenia gravis to see if it helps symptoms while checking safety and how the drug behaves in the body.

  Recruiting at 8 sites Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07596784

• Ravulizumab in Chinese adults with NMOSD

  This study tests ravulizumab in Chinese adults with NMOSD who are AQP4 antibody positive to see if it helps reduce relapses and is safe.

  Recruiting Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07557420

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.